Chikungunya

Delhi reports 5-year high in chikungunya, malaria cases; dengue declines

Delhi registered a record high number of Chikungunya and Malaria cases in the past five years, while dengue cases declined, according to official data. As of November 9 this year, 728 malaria cases and 172 chikungunya cases were reported in the city. In 2020, there were 228 malaria cases, in 2021, 167 cases, in 2022, 263 cases, and in 2023, 426 cases. The tally includes 19 cases reported in the week leading up to November 9, according to the Municipal Corporation of Delhi's weekly report on mosquito-borne diseases. The number of chikungunya cases in 2020 stood at 111, in 2021, there were 89 cases, in 2022, 48 cases, and in 2023, 65 cases. This year, as of November 9, the number of chikungunya cases was 172. Meanwhile, 4,533 dengue cases were reported in Delhi in 2024, including 472 cases in November. In comparison, there were 9,266 dengue cases reported in 2023. The number of dengue cases has sharply declined since last month, when it doubled to 2,431 cases from 1,052 cases in

Death risk from chikungunya continues for up to 3 months: Lancet study

People infected with the chikungunya virus continue to have an increased risk of death for up to three months post-infection, according to a study published in The Lancet Infectious Diseases journal. Chikungunya is a viral disease transmitted by mosquitoes to humans. Most commonly, the virus is transmitted by Aedes aegypti and Aedes albopictus mosquitoes, more commonly known as yellow fever and tiger mosquitoes, respectively. While most patients recover fully, chikungunya disease can prove fatal. Despite infections going largely unreported, approximately five lakh cases and over 400 deaths were recorded worldwide in 2023, the researchers said. "With chikungunya infections expected to increase, it's important that health services consider the risks that persist even after the acute phase of infection has ended," said Enny Da Paixao Cruz, Associate Professor at the London School of Hygiene & Tropical Medicine (LSHTM), UK, and senior author of the study. The researchers analysed ...

India witnesses decline in vector-borne tropical diseases in last 2 years

NCVBDC numbers reveal a downward trend in these diseases over the past few years, indicating successful control efforts

First chikungunya vaccine, Ixchiq, approved by US FDA for people above 18

Ixchiq, the first chikungunya vaccine, has been approved by the US Food and Drug Administration (FDA) for individuals 18 years of age and older who are at increased risk of exposure to mosquito-borne virus. Containing a live, weakened version of the chikungunya-causing virus, Ixchiq is administered as a single dose by injection into the muscle and may cause symptoms in the recipient similar to those experienced by people having the viral disease, the FDA said in a statement. "Infection with chikungunya virus can lead to severe disease and prolonged health problems, particularly for older adults and individuals with underlying medical conditions," said Peter Marks, director of the FDA's Center for Biologics Evaluation and Research. "Today's approval addresses an unmet medical need and is an important advancement in the prevention of a potentially debilitating disease with limited treatment options," said Marks. The effectiveness of the vaccine was determined through a clinical study

US approves 1st vaccine against chikungunya virus: All you need to know

Symptoms of chikungunya can sometimes last for months or even years, but the virus is rarely fatal

Valneva's experimental vaccine for Chikungunya shows immune response

The stock rose as much as 3.4 per cent in Paris trading

One-shot chikungunya vaccine found safe, effective in first phase 3 trial

A single-dose vaccine for chikungunya was found safe and produced a strong immune response against the viral disease, according to the first phase 3 trial of the preventive published in The Lancet journal. However, the researchers were unable to investigate whether the VLA1553 vaccine, developed by French biotech company Valneva, protects against subsequent disease since the study was not conducted in regions where chikungunya is endemic. Chikungunya is a mosquito-borne disease caused by the chikungunya virus (CHIKV), which is endemic in some regions of Africa, Asia, and the Americas. It causes a fever in patients roughly four to eight days after they have been bitten by an infected mosquito. Symptoms include headaches, fatigue, nausea, and severe muscle and joint pain. The joint pain is often debilitating and usually lasts for a few days but may be prolonged, lasting for weeks, months or even years. Serious disease and death is rare, but older people and newborn babies are most a

Climate change can drive global outbreaks in dengue, Chikungunya: WHO

These diseases, that spread from mosquitoes to people, are causing an increasing number of outbreaks worldwide, with climate change, deforestation and urbanisation being some of the major risk factors

Delhi dengue outbreak: 321 cases in first 5 days of Oct, tally at 1,258

As many as 693 cases were reported in September alone, according to a report released by the MCD

What is Chikungunya? Symptoms, treatment, prevention, and other details

Death from chikungunya is rare but it can cause severe health issues in some people. Here are more details about the illness, its symptoms, and prevention methods

Mylab launches combined RT-PCR test for Zika, malaria, dengue

Test can differentiate between seven diseases and give results in 2 hrs

Dengue, chikungunya, malaria notifiable under Epidemic Diseases Act

The notification makes it compulsory for all hospitals to provide information to the government about any such case that they receive.

What are Vector-borne diseases? Here're symptoms, history in numbers

These diseases account for more than 17 per cent of all infectious diseases, causing over seven lakh deaths across the world annually.

CEPI to grant $14 mn for trial of Bharat Biotech's Chikungunya vaccine

The vaccine completed standard pre-clinical studies, and an optimum immune response was elicited by the adjuvant vaccine in phase-1 trials in India

Combating Aedes

Researchers have discovered that a common bacteria, wolbachia, can inhibit virus infections in mosquitoes

Drug to fight Chikungunya virus identified by IIT Roorkee scientists

Chikungunya is becoming a major public health concern with many people being affected by it year after year

Chikungunya finds promising results with Homeopathy treatment

Chikungunya is a viral disease transmitted to humans by infected mosquitoes

Chikungunya, dengue outbreak: Above 100 cases registered in Delhi this year

4,431 cases of dengue and 9,749 chikungunya were reported in 2016 and

Chikungunya cases fall in Delhi, dengue crosses 4,000-mark

As per the report, 152 fresh dengue cases were reported in Delhi last week. 4,065 cases were recorded till Nov 19

10,851 chikungunya cases in Delhi

Of the total chikungunya cases, nearly 720 of them have been reported in areas falling under the NDMC